Page last updated: 2024-08-24

gemcitabine and mln 8237

gemcitabine has been researched along with mln 8237 in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (66.67)	24.3611
2020's	1 (33.33)	2.80

Authors

Authors	Studies
Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ	1
Almasan, A; Dreicer, R; Ecsedy, JA; Hansel, DE; Lindner, D; Mir, MC; Parker, Y; Singh, K; Teh, BT; Zhang, Z; Zhou, N	1
Chen, JA; Gandara, DR; Huynh, JC; Kelly, KL; Kim, EJ; Li, T; Mack, PC; Mahaffey, N; Martinez, A; Matsukuma, K; Riess, JW; Semrad, TJ; Tam, K; Wu, CY; Yu, AM	1

Trials

1 trial(s) available for gemcitabine and mln 8237

Article	Year
A phase I dose escalation, dose expansion and pharmacokinetic trial of gemcitabine and alisertib in advanced solid tumors and pancreatic cancer. Cancer chemotherapy and pharmacology, 2022, Volume: 90, Issue:3 Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Azepines; Deoxycytidine; Gemcitabine; Humans; Maximum Tolerated Dose; Neoplasms; Pancreatic Neoplasms; Pyrimidines	2022

Other Studies

2 other study(ies) available for gemcitabine and mln 8237

Article	Year
Identification of potent Yes1 kinase inhibitors using a library screening approach. Bioorganic & medicinal chemistry letters, 2013, Aug-01, Volume: 23, Issue:15 Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship	2013
The investigational Aurora kinase A inhibitor MLN8237 induces defects in cell viability and cell-cycle progression in malignant bladder cancer cells in vitro and in vivo. Clinical cancer research : an official journal of the American Association for Cancer Research, 2013, Apr-01, Volume: 19, Issue:7 Topics: Aneuploidy; Animals; Apoptosis; Aurora Kinase A; Aurora Kinases; Azepines; Cell Cycle; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Survival; Cluster Analysis; Deoxycytidine; Drug Synergism; Gemcitabine; Gene Expression; Gene Expression Profiling; Humans; M Phase Cell Cycle Checkpoints; Mice; Neoplasm Invasiveness; Paclitaxel; Phenotype; Protein Serine-Threonine Kinases; Pyrimidines; Tumor Burden; Urinary Bladder Neoplasms; Xenograft Model Antitumor Assays	2013

Article

Year

Identification of potent Yes1 kinase inhibitors using a library screening approach.

Bioorganic & medicinal chemistry letters, 2013, Aug-01, Volume: 23, Issue:15

Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship

2013

The investigational Aurora kinase A inhibitor MLN8237 induces defects in cell viability and cell-cycle progression in malignant bladder cancer cells in vitro and in vivo.

Clinical cancer research : an official journal of the American Association for Cancer Research, 2013, Apr-01, Volume: 19, Issue:7

Topics: Aneuploidy; Animals; Apoptosis; Aurora Kinase A; Aurora Kinases; Azepines; Cell Cycle; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Survival; Cluster Analysis; Deoxycytidine; Drug Synergism; Gemcitabine; Gene Expression; Gene Expression Profiling; Humans; M Phase Cell Cycle Checkpoints; Mice; Neoplasm Invasiveness; Paclitaxel; Phenotype; Protein Serine-Threonine Kinases; Pyrimidines; Tumor Burden; Urinary Bladder Neoplasms; Xenograft Model Antitumor Assays

2013